Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis

被引:0
|
作者
Pietro Lampertico
Stefan Mauss
Marcello Persico
Stephen T. Barclay
Steven Marx
Kristina Lohmann
Mark Bondin
ZhenZhen Zhang
Fiona Marra
Pamela S. Belperio
Heiner Wedemeyer
Steven Flamm
机构
[1] Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico,Division of Gastroenterology and Hepatolgy, CRC “A.M. and A.Migliavacca” Center for Liver Disease
[2] University of Milan,Department of Pathophysiology and Transplantation
[3] Center for HIV and Hepatogastroenterology,Internal Medicine and Hepatology Unit
[4] University of Salerno,Department of Life Sciences
[5] Glasgow Caledonian University,Department of Veterans Affairs
[6] Gastroenterology,Department of Gastroenterology and Hepatology
[7] Glasgow Royal Infirmary,Department of Gastroenterology, Hepatology and Endocrinology
[8] AbbVie Inc.,undefined
[9] AbbVie Deutschland GmBH Co. KG,undefined
[10] University of Liverpool Hepatology Drug Interactions Group,undefined
[11] VA Palo Alto Healthcare System,undefined
[12] Essen University Hospital,undefined
[13] Leberstiftungs-GmbH Deutschland,undefined
[14] Hannover Medical School,undefined
[15] Northwestern University Feinberg School of Medicine,undefined
来源
Advances in Therapy | 2020年 / 37卷
关键词
Fibrosis; Hepatitis C; Infectious disease; Review; Therapeutics;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:4033 / 4042
页数:9
相关论文
共 50 条
  • [41] Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
    Xavier Forns
    Jordan J. Feld
    Douglas E. Dylla
    Stanislas Pol
    Kazuaki Chayama
    Jinlin Hou
    Jeong Heo
    Pietro Lampertico
    Ashley Brown
    Mark Bondin
    Fernando Tatsch
    Margaret Burroughs
    John Marcinak
    Zhenzhen Zhang
    Amanda Emmett
    Stuart C. Gordon
    Ira M. Jacobson
    Advances in Therapy, 2021, 38 : 3409 - 3426
  • [42] Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C
    Buggisch, Peter
    Vermehren, Johannes
    Mauss, Stefan
    Guenther, Rainer
    Schott, Eckart
    Pathil, Anita
    Boeker, Klaus
    Zimmermann, Tim
    Teuber, Gerlinde
    Vornkahl, Heike-Pfeiffer
    Simon, Karl-Georg
    Niederau, Claus
    Wedemeyer, Heiner
    Zeuzem, Stefan
    JOURNAL OF HEPATOLOGY, 2018, 68 (04) : 663 - 671
  • [43] EFFICACY AND SAFETY OF 8-WEEK GLECAPREVIR/PIBRENTASVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND COMPENSATED CIRRHOSIS: EXPEDITION-8 COMPLETE RESULTS
    Brown, Robert S., Jr.
    Buti, Maria
    Rodrigues, Lino
    Chulanov, Vladimir
    Chuang, Wan Long
    Aguilar, Humberto
    Horvath, Gabor
    Zuckerman, Elimelech
    Rosado-Carrion, Barbara
    Rodriguez-Perez, Federico
    Urbanek, Petr
    Abergel, Armand
    Cohen, Eric
    Lovell, Sandra Sinisi
    Schnell, Gretja
    Lin, Chih-Wei
    Zha, Jiuhong
    Wang, Stanley
    Trinh, Roger
    Mensa, Federico J.
    Burroughs, Margaret
    Felizarta, Franco
    HEPATOLOGY, 2019, 70 (06) : 1493A - 1494A
  • [44] y Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
    Naganuma, Atsushi
    Chayama, Kazuaki
    Notsumata, Kazuo
    Gane, Edward
    Foster, Graham R.
    Wyles, David
    Kwo, Paul
    Crown, Eric
    Bhagat, Abhi
    Mensa, Federico J.
    Otani, Tetsuya
    Larsen, Lois
    Burroughs, Margaret
    Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY, 2019, 54 (08) : 752 - 761
  • [45] Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis
    Lampertico, Pietro
    Carrion, Jose A.
    Curry, Michael
    Turnes, Juan
    Cornberg, Markus
    Negro, Francesco
    Brown, Ashley
    Persico, Marcello
    Wick, Nicole
    Porcalla, Ariel
    Pangerl, Andreas
    Crown, Eric
    Larsen, Lois
    Yu, Yao
    Wedemeyer, Heiner
    JOURNAL OF HEPATOLOGY, 2020, 72 (06) : 1112 - 1121
  • [46] A real-world clinical application of the combination therapy with glecaprevir/pibrentasvir to special population in chronic hepatitis C patients
    Sato, Ken
    Yamazaki, Yuichi
    Kobayashi, Takeshi
    Tojima, Hiroaki
    Horiguchi, Norio
    Kakizaki, Satoru
    Uraoka, Toshio
    Ohnishi, Hiroshi
    Okamoto, Hiroaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 444 - 444
  • [47] High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
    Puoti, Massimo
    Foster, Graham R.
    Wang, Stanley
    Mutimer, David
    Gane, Edward
    Moreno, Christophe
    Chang, Ting Tsung
    Lee, Samuel S.
    Marinho, Rui
    Dufour, Jean-Francois
    Pol, Stanislas
    Hezode, Christophe
    Gordon, Stuart C.
    Strasser, Simone I.
    Thuluvath, Paul J.
    Zhang, Zhenzhen
    Lovell, Sandra
    Pilot-Matias, Tami
    Mensa, Federico J.
    JOURNAL OF HEPATOLOGY, 2018, 69 (02) : 293 - 300
  • [48] Effectiveness of 8 weeks of glecaprevir/pibrentasvir in treatment-naive hepatitis C patients with liver cirrhosis: results from the real-world Spanish Hepa-C registry
    Turnes, Juan
    Hernandez-Guerra, Manuel
    Souto Rodriguez, Raquel
    Fernandez, Inmaculada
    Carrion, Jose A.
    de Cuenca Moron, Beatriz
    Manuel Pascasio, Juan
    Moreno Planas, Jose Maria
    Moreno, Jose Juan
    Bellot, Pau
    Delgado, Manuel
    Salmeron, Javier
    Marino, Zoe
    Rosales Zabal, Jose Miguel
    Garcia-Samaniego Rey, Francisco Javier
    Morillas, Rosa
    Diago, Moises
    Crespo, Javier
    Gonzalez Santiago, Jesus
    Mateos Munoz, Beatriz
    Torras, Xavier
    Badia-Aranda, Esther
    Bonet, Lucia
    Menendez, Fernando
    Bernal Monterde, Vanesa
    Marquez Rodriguez, Paqui
    Arenas, Juan
    Prieto, Martin
    Perez Cachafeiro, Santiago
    JOURNAL OF HEPATOLOGY, 2020, 73 : S346 - S347
  • [49] Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis
    Vered Rosenberg
    Gabriel Chodick
    Zhenyi Xue
    Freddy Faccin
    Howard Amital
    Advances in Therapy, 2023, 40 : 4504 - 4522
  • [50] Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
    Robert J. Fontana
    Sabela Lens
    Stuart McPherson
    Magdy Elkhashab
    Victor Ankoma-Sey
    Mark Bondin
    Ana Gabriela Pires dos Santos
    Zhenyi Xue
    Roger Trinh
    Ariel Porcalla
    Stefan Zeuzem
    Advances in Therapy, 2019, 36 : 3458 - 3470